secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cue Biopharma, Inc. (CUE)
CIK:        0001645460
Form:       8-K
Filed at:   2024-08-16T23:59:59+00:00
Accession:  0000950170-24-098032
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Cue Biopharma receives Nasdaq deficiency notice for bid price below $1.00
-------------------------------------------------------------------------

- Received Nasdaq notice on August 15, 2024 for failure to meet minimum bid price of $1.00 for 30 consecutive business days.
- Has 180 calendar days (until Feb 11, 2025) to regain compliance by having bid price ≥$1.00 for 10 consecutive business days.
- If not compliant, may qualify for another 180-day period, subject to meeting other listing standards.
- Company will evaluate options including potential reverse stock split to cure deficiency.
- No assurance of regaining compliance; stock remains listed pending cure or potential delisting appeal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645460/000095017024098032/0000950170-24-098032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645460/000095017024098032/cue-20240815.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-098032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer